ZLAB
$19.02
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Recent News
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
Asian equities traded in the US as American depositary receipts were tracking higher Friday morning,
Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading
Asian equities traded in the US as American depositary receipts were modestly higher Wednesday morni
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Monday Trading
Asian equities traded in the US as American depositary receipts started the week sharply lower Monda
Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump?
If you are wondering whether Zai Lab's current share price reflects its true worth, you are not alone. Many investors are asking whether the recent moves line up with the fundamentals. The stock trades at US$19.22 after a 15.8% gain over the last 30 days, although the 1 year return of a 44.5% decline and 5 year return of an 86.0% decline show a very different story. Recent headlines around Zai Lab have focused on its position in the pharmaceuticals and biotech space and how markets are...
Zai Lab Q4 Earnings Call Highlights
Zai Lab (NASDAQ:ZLAB) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline progress toward a more globally oriented pipeline while emphasizing that the company’s China commercial business remains a key source of stability and funding for research and development.